FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:1463-1466 May 14, 1998 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Fox, I. J. PubMed Citation

Attempts to treat a variety of conditions, including type I diabetes mellitus and fulminant liver failure, with epithelial-cell transplantation have been disappointing. In this issue of the Journal, Fox and colleagues report partial correction of the metabolic defect of Crigler–Najjar syndrome type I by transplantation of isolated, allogeneic human hepatocytes.¹ They have shown that hepatocyte transplantation is relatively easy to accomplish. Although their report is based on one hepatocyte infusion in one patient, the procedure was safe and relatively inexpensive as compared with orthotopic liver transplantation.

Hepatocyte transplantation has been proposed for two types of situations: as "gene therapy" for . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Mitchell, C., Mignon, A., Guidotti, J. E., Besnard, S., Fabre, M., Duverger, N., Parlier, D., Tedgui, A., Kahn, A., Gilgenkrantz, H. (2000). Therapeutic liver repopulation in a mouse model of hypercholesterolemia. Hum Mol Genet 9: 1597-1602 [Abstract] [Full Text]